Inve India ▾

Sun Pharma Advanced Research Company share price & results

Sun Pharma Advanced Research Company Limited· Healthcare

Results to
Jun 2026
Latest analysed call
Q3 FY26
Ownership as of
Sept 2026

R&D-only biopharma inventing oncology/immunology drugs, licensed out to Sun Pharma and other partners.

Company research is public. Sign in to keep your own companies, notes and cases.

Reported

The figures, each with its period

Each figure keeps its basis and period; nothing is filled in.

MetricValueChangeBasisPeriodNote
Revenue40.0 ₹ crore+300.0% YoYQuarterly, as filedQuarter to Jun 2026Revenue from operations as filed.
Operating margin-85.0 %+455.0 pts YoYOperating profit / revenueQuarter to Jun 2026For the quarter; a change is in percentage points.
Net profit-21.0 ₹ crore—Quarterly, as filedQuarter to Jun 2026Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown.
Return on equity119.28 %+160.5 ptsFY Mar 2026 vs FY Mar 2023Trailing twelve monthsTTM to Jun 2026Adjusted profit attributable to owners ÷ average owners’ equity.
Free cash flow margin-13.97 %+21.1 ptsFY Mar 2026 vs FY Mar 2023Fiscal yearFY ending Mar 2026(Operating cash flow − fixed-asset purchases + disposals) ÷ revenue.
Revenue growth (YoY)Unavailable+62.9 ptsFY Mar 2025 vs FY Mar 2024Trailing twelve monthsTTM to Jun 2026Not in the analysed materials. No older figure is substituted.

Source: Inve data from filed results; ratios from the Screener-verified panel · to Jun 2026

Guidance

What management said, and what became of it

3 of 7 judged targets kept · 10 open · verdicts reflect calls analysed to Q3 FY26.

Sun Pharma Advanced Research Company Limited management guidance track record on Inve: 17 targets tracked across analysed earnings calls (3 achieved, 4 missed, 10 open).

TargetOriginal wordingSaidLatest callVerdict
PROSEEK (PD Phase-2) Data ReadoutComing financial year (H2 FY24)Q1 FY23Q3 FY26:The trial failure is a past event and was not discussed. The outcome remains a miss.
Call transcript, Q3 FY26 · 13 Jan 2026		Missed
Cash RunwayEnd of FY'24Q1 FY23Q3 FY26:Reiterated that the company is finalizing a funding plan to extend the cash window to FY'28, with completion hoped for in H1 2026. The previous runway is exhausted and the new funding is not yet secured.
Call transcript, Q3 FY26 · 13 Jan 2026		At Risk
SCD-153 Phase 1B Interim ReadoutQ4 of the calendar year 2026
Call transcript, Q3 FY26 · 13 Jan 2026		Q3 FY26Q3 FY26:An interim readout from the Phase 1B study in alopecia areata is expected in the Q4 of the calendar year 2026.
Call transcript, Q3 FY26 · 13 Jan 2026		New

Source: Inve Guidance Tracker for Sun Pharma Advanced Research Company Limited · to Q3 FY26

A verdict describes what became of management’s own words in later analysed calls. “Delayed” is a change of date, “went quiet” a target the calls stopped mentioning. None of it is a judgement on the investment. The methodology sets out how verdicts are recorded.

4 of Sun Pharma Advanced Research Company Limited's 17 targets were missed. See which ones, and which are quietly gone. The 3 above are the free sample; 14 more targets are in the full ledger.

Free account: 5 full ledgers a month and one Inve Case. Pro opens 100 a month, ₹499.
See the full record

Price

₹178.4 +3.86% · +₹6.63

Last close 26 Oct 2026 · NSE · INR · Source: Inve

Performance +35.8% 1Y

₹100₹150₹200₹250Oct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26Oct 26Q2 FY26 — 8 Jan 2026Q3 FY26 — 13 Jan 2026

1Y: ₹131.37 on 24 Oct 2025 → ₹178.4. High ₹277.57 (9 Jul 2026), low ₹108.71 (23 Mar 2026).

Previous close
₹171.77
Market cap
₹5.8k Cr
52-week range
₹108.71 – ₹277.57
One year
+33.87%
Price to earnings (TTM to Jun 2026)
3.63×
Return on equity (TTM to Jun 2026)
119.28%

Overview

Symbol
NSE:SPARC
Exchange
NSE
Currency
INR

What Sun Pharma Advanced Research Company Limited does

Based on the company's own presentations, annual report and earnings calls.

SPARC is a research-and-development company, not a manufacturer or direct seller of medicines: it discovers and develops small-molecule and biologic drug candidates focused on oncology and immunology, then out-licenses the resulting intellectual property to pharmaceutical partners (including promoter-group entity Sun Pharmaceutical Industries) rather than commercializing products itself. It earns through structured licensing arrangements - upfront fees, milestone payments tied to regulatory approval and commercial success, and royalties on eventual product sales. Discovery and clinical-development work is carried out from its own research centres in Gujarat and Mumbai, supported by a wholly-owned US subsidiary, SPARCLIFE Inc., for overseas trial operations. Its pipeline spans an antibody-drug conjugate for solid tumours, a topical new chemical entity for alopecia areata/vitiligo, and earlier-stage assets in ophthalmology and oncology.

R&D / research centres
4 (Registered Office & Research Centre + 2 further Research Centres in Vadodara, Gujarat; 1 Corporate Office & Research Centre in Mumbai)
Geographic footprint
India (Vadodara, Mumbai) plus a branch office in New Jersey, USA
Subsidiaries
1 wholly-owned subsidiary - SPARCLIFE Inc. (incorporated in Delaware, USA, Sept 2023)
Therapeutic focus areas
Oncology and Immunology
Scientific workforce share
~85% of employees are scientists
Business model
Pure out-licensing / royalty model - no direct drug manufacturing or commercial sales force
Headquarters Mumbai, India (Corporate Office); Registered Office in Vadodara, GujaratEmployees 316 (FY2024-25 (as of March 3) Company website

How the price took the results

close before → close after

Q3 FY26
+0.4%
13 Jan
Q2 FY26
−2.0%
8 Jan

The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.

Your own record

Start an Inve Case for Sun Pharma Advanced Research Company Limited

Free account: one company. Everything above stays public.

Write why you follow Sun Pharma Advanced Research Company Limited and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.

What an account adds

Keep reading

Other Healthcare companies

All Healthcare companies → · Healthcare earnings growth →

Learn to analyse Sun Pharma Advanced Research Company Limited

Guides on how to read this kind of business and the numbers that matter.